U.S. Vaginal Sling, Benign Prostatic Hyperplasia Device and Prostate Cancer Treatment Device Markets Will Rebound Through 2022

BURLINGTON, Mass., March 4, 2014 /PRNewswire/ -- Decision Resources Group finds that the United States market for urological devices will expand to over $2.6 billion by 2022. While some formerly high-growth segments, including vaginal slings, benign prostatic hyperplasia (BPH) treatment devices and prostate cancer treatment devices, declined in 2013, various factors will fuel a rebound in these markets in the years ahead.

"The vaginal sling market has suffered in recent years due to widespread media coverage of Food and Drug Administration (FDA) warnings related to transvaginal meshes even though most of this had to do with pelvic floor reconstruction products," said Decision Resources Group Senior Analyst Lexie Code. "Because many patients are unaware of the differences between pelvic organ prolapse meshes and vaginal slings, the negative coverage significantly affected the vaginal sling market. However, physicians, professional associations and manufacturers are continuing efforts to educate patients on the fact that certain types of vaginal slings, such as transobturator and retropubic slings, represent the gold standard treatment for incontinence and have been deemed safe and effective by the FDA. As a result, demand for vaginal slings will rebound, allowing the market to slowly recover."

In the BPH and prostate cancer treatment device markets, procedure volumes will also be impeded by several factors. Pharmaceutical alternatives as well as dissatisfaction with retreatment rates for certain office-based and laser treatments will limit BPH procedure volumes, while concerns regarding overtreatment will inhibit prostate cancer treatments.

Nonetheless, both segments will recover through 2022. Positive clinical results, product improvements and growth of emerging treatments like embolization will allow the BPH device market to return to positive growth from 2018 onward. The prostate cancer treatment device segment will also bounce back, supported by the stabilization of treatment patterns and growing interest in focal therapy, which allows for the application of brachytherapy or cryoablation to only the diseased portion of the prostate rather than the entire gland.

Combined with favorable demographics and continued demand for minimally invasive treatment options with long-term effectiveness, the renewed growth of the vaginal sling, BPH device and prostate cancer treatment device markets will ultimately allow for expansion of the U.S. urological device market through 2022.

Decision Resources Group's US Markets for Urological Devices 2014 report includes procedure, unit average selling price and revenue information, along with market drivers and limiters and a competitive landscape for urinary incontinence devices, stone management devices, benign prostatic hyperplasia devices, urological endoscopes, prostate cancer treatment devices and erectile dysfunction treatment devices in the United States.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Logo - http://photos.prnewswire.com/prnh/20130103/MM36768LOGO

SOURCE Decision Resources Group